Clinical Trial

Treatment of Metastatic Prostate Cancer

Study Description

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Niraparib

Participants will receive niraparib 200 mg (2 capsules of 100 mg each) capsules once daily.

Drug - Abiraterone Acetate

Participants will receive abiraterone acetate 1000 mg (4 tablets of 250 mg each) tablets once daily.

Drug - Prednisone

Participants will receive prednisone 10 mg (2 tablets of 5 mg each) tablets daily.

Drug - Placebo

Participants will receive matching placebo capsules once daily.

Additional Information

Official Study Title

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

Clinical Trial ID

NCT03748641

ParticipAid ID

bkR6Xa